mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Previous studies have suggested that inhibition of the mammalian target of rapamycin (mTOR) by rapamycin suppresses myocardial hypertrophy. However, the role of mTOR in the progression of cardiac dysfunction in pathological hypertrophy has not been fully defined. Interestingly, recent reports indicate that the inflammatory response, which plays an important role in the development of heart failure, is enhanced by rapamycin under certain conditions. Our aim in this study was to determine the influence of mTOR on pathological hypertrophy and to assess whether cardiac mTOR regulates the inflammatory response. We generated transgenic mice with cardiac-specific overexpression of wild-type mTOR (mTOR-Tg). mTOR-Tg mice were protected against cardiac dysfunction following left ventricular pressure overload induced by transverse aortic constriction (TAC) ( P < 0.01) and had significantly less interstitial fibrosis compared with littermate controls (WT) at 4 wk post-TAC ( P < 0.01). In contrast, TAC caused cardiac dysfunction in WT. At 1 wk post-TAC, the proinflammatory cytokines interleukin (IL)-1β and IL-6 were significantly increased in WT mice but not in mTOR-Tg mice. To further characterize the effects of mTOR activation, we exposed HL-1 cardiomyocytes transfected with mTOR to lipopolysaccharide (LPS). mTOR overexpression suppressed LPS-induced secretion of IL-6 ( P < 0.001), and the mTOR inhibitors rapamycin and PP242 abolished this inhibitory effect of mTOR. In addition, mTOR overexpression reduced NF-κB-regulated transcription in HL-1 cells. These data suggest that mTOR mitigates adverse outcomes of pressure overload and that this cardioprotective effect of mTOR is mediated by regulation of the inflammatory reaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618
Claycomb, W. C., Lanson, N. A., Stallworth, B. S., Egeland, D. B., Delcarpio, J. B., Bahinski, A., & Izzo, N. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2979 · Cited by 1,546
The TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory Response
Weichhart, T., Costantino, G., Poglitsch, M., Rosner, M., Zeyda, M., Stuhlmeier, K. M., Kolbe, T., Stulnig, T. M., Hörl, W. H., Hengstschläger, M., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.012 · Cited by 801
Makarenko, I., Opitz, C. A., Leake, M. C., Neagoe, C., Kulke, M., Gwathmey, J. K., del Monte, F., Hajjar, R. J., & Linke, W. A. (2004) · Circulation Research · doi:10.1161/01.res.0000143901.37063.2f · Cited by 332
Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells
Schmitz, F., Heit, A., Dreher, S., Eisenächer, K., Mages, J., Haas, T., Krug, A., Janssen, K., Kirschning, C. J., & Wagner, H. (2008) · European Journal of Immunology · doi:10.1002/eji.200838761 · Cited by 212
Cited by
New Insights Into the Role of mTOR Signaling in the Cardiovascular System
Sciarretta, S., Forte, M., Frati, G., & Sadoshima, J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311147 · Cited by 491
Mammalian Target of Rapamycin Signaling in Cardiac Physiology and Disease
Sciarretta, S., Volpe, M., & Sadoshima, J. (2014) · Circulation Research · doi:10.1161/circresaha.114.302022 · Cited by 453
Schirone, L., Forte, M., Palmerio, S., Yee, D., Nocella, C., Angelini, F., Pagano, F., Schiavon, S., Bordin, A., Carrizzo, A., et al. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/3920195 · Cited by 425
BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure
Anand, P., Brown, J. D., Lin, C. Y., Qi, J., Zhang, R., Artero, P. C., Alaiti, M. A., Bullard, J., Alazem, K., Margulies, K. B., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.013 · Cited by 406
“(Figure 4D) typically seen after 4 weeks of TAC (Sano et al., 2007; Song et al., 2010).”
The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy
Wang, Z., Zhang, X.-J., Ji, Y.-X., Zhang, P., Deng, K.-Q., Gong, J., Ren, S., Wang, X., Chen, I., Wang, H., et al. (2016) · Nature Medicine · doi:10.1038/nm.4179 · Cited by 386
Baba, Y., Higa, J. K., Shimada, B. K., Horiuchi, K. M., Suhara, T., Kobayashi, M., Woo, J. D., Aoyagi, H., Marh, K. S., Kitaoka, H., et al. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00452.2017 · Cited by 347
Self-citationLate-life rapamycin treatment reverses age-related heart dysfunction
Flynn, J. M., O'Leary, M. N., Zambataro, C. A., Academia, E. C., Presley, M. P., Garrett, B. J., Zykovich, A., Mooney, S. D., Strong, R., Rosen, C. J., et al. (2013) · Aging Cell · doi:10.1111/acel.12109 · Cited by 311
Suetomi, T., Willeford, A., Brand, C. S., Cho, Y., Ross, R. S., Miyamoto, S., & Brown, J. H. (2018) · Circulation · doi:10.1161/circulationaha.118.034621 · Cited by 304
Sciarretta, S., Zhai, P., Shao, D., Maejima, Y., Robbins, J., Volpe, M., Condorelli, G., & Sadoshima, J. (2012) · Circulation · doi:10.1161/circulationaha.111.078212 · Cited by 292
Palomer, X., Salvadó, L., Barroso, E., & Vázquez-Carrera, M. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.150 · Cited by 289
Gao, G., Chen, W., Yan, M., Liu, J., Luo, H., Wang, C., & Yang, P. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4407 · Cited by 219
“Therefore, rapamycin is often used as an inhibitor of protein synthesis and cell growth to examine its effects on myocardial hypertrophy or cardiac remodeling in pressure-overloaded heart disease (52-55).”
BackgroundPhosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Aoyagi, T., & Matsui, T. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796390976 · Cited by 213
Self-citationFuel availability and fate in cardiac metabolism: a tale of two substrates
Pascual, F., & Coleman, R. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.03.014 · Cited by 125
“Of note, cardiac hypertrophy is not induced by expression of constitutively active mTORC1 or by overexpression of wild-type mTORC1 [109, 110].”
BackgroundChang, K., Kang, P., Liu, Y., Huang, K., Miao, T., Sagona, A. P., Nezis, I. P., Bodmer, R., Ocorr, K., & Bai, H. (2020) · Autophagy · doi:10.1080/15548627.2019.1704117 · Cited by 73
Metadata
- Authors
- Song, X., Kusakari, Y., Xiao, C.-Y., Kinsella, S. D., Rosenberg, M. A., Scherrer-Crosbie, M., Hara, K., Rosenzweig, A., & Matsui, T.
- Venue
- American Journal of Physiology-Cell Physiology
- Publisher
- American Physiological Society
- Published
- 2010-12
- Volume
- 299
- Issue
- 6
- Pages
- C1256-C1266
- ISSN
- 0363-6143 (ISSN-L)
- 1522-1563
- OpenAlex
- W2114741231
- Cited by
- 133
- References
- 5
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.